Anavex Life Sciences Corp (OTCMKTS:AVXL), a sought after biopharmaceutical company seems delighted after witnessing the data published by Proceedings of the National Academy of Sciences. Anavex is known for developing various drug candidates for treating central nervous system diseases, Alzheimer’s disease and different types of cancers.
The primary reason behind Anavex’s encouragement is nothing but the research work done by Anavex. As per the reports, the research determines that if the sigma-1 receptor is activated with agonists, it can easily reducd the impact of tau dysfunction.
What’s Tau Dysfuction:
The abnormal tau phosphorylation is a common sign of various neurodegenerative diseases. If taken into consideration various neurodegenerative diseases, one can understand the fact that Alzheimer’s is the most widely known type among them. Alzheimer’s is associated with tau protein along with frontotemporal dementia and progressive supranuclear palsy in the brain.
Earlier, researchers found that ANAVEX 2-73, which target sigma-1 receptor, blocked amyloid-beta and tau proteins as well as various other memory deficits in a mouse model of deathly Alzheimer’s. The data was published for the first time in Neuropsychopharmacology, an international scientific journal. A negative progress in both of these hallmarks can be stoppedd, reversed or slowed.
Currently, ANAVEX 2-73 is in phase 2a study, and the company is anticipating to recieve the primary data within next few months. If everything goes as per plans, it will look forward to reporting preliminary data in 3Q2015.
The senior management of the company is delighted to see this development. According to Christopher U. Missling, CEO and President, Anavex Life Sciences Corp (OTCMKTS:AVXL), the current progress in the research unveils the true potential for sigma-1 drug therapeutics to stop tau toxicity in Alzheimer’s and other diseases. The research team has come across quite a few valuable findings and looks forward to reporting primary results within a few months time.